Lista de obras - Harald Herrmann - Dominio Público Uruguay

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

artículo científico publicado en 2012

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

artículo científico publicado en 2009

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

artículo científico publicado en 2014

Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.

artículo científico publicado en 2010

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

artículo científico publicado en 2011

CD52 is a molecular target in advanced systemic mastocytosis.

artículo científico publicado en 2014

Cancer stem cell definitions and terminology: the devil is in the details.

artículo científico publicado en 2012

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

artículo científico publicado en 2015

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

artículo científico publicado en 2017

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia

artículo científico publicado en 2014

Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression

artículo científico publicado en 2011

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

artículo científico publicado en 2014

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

artículo científico publicado en 2017

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia

artículo científico publicado en 2017

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

artículo científico publicado en 2016

Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

artículo científico publicado en 2017

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H

artículo científico publicado en 2013

Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.

artículo científico publicado en 2012

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

artículo científico publicado en 2011

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

artículo científico publicado en 2015

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

artículo científico publicado en 2014

Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression

artículo científico publicado en 2012

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

artículo científico publicado en 2015

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

artículo científico publicado en 2014

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

artículo científico publicado en 2014

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

artículo científico publicado en 2011

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

artículo científico publicado en 2009

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

artículo científico publicado en 2010

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice

artículo científico publicado en 2010

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

artículo científico publicado en 2012

Neoplastic stem cells: current concepts and clinical perspectives.

scientific article published on 25 February 2010

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model

artículo científico publicado en 2012

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

artículo científico publicado en 2010

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

artículo científico publicado en 2011

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells

artículo científico publicado en 2015

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

artículo científico publicado en 2016

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

artículo científico publicado en 2011

Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.

artículo científico publicado en 2009

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

artículo científico publicado en 2012

Structure and assembly properties of the intermediate filament protein vimentin: the role of its head, rod and tail domains

artículo científico publicado en 1996

Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

artículo científico publicado en 2009

Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.

artículo científico publicado en 2009

The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells

artículo científico publicado en 2012

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

artículo científico publicado en 2012

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils

artículo científico publicado en 2008

The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

artículo científico

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

artículo científico publicado en 2010

Lista de obras de Harald Herrmann

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

CD52 is a molecular target in advanced systemic mastocytosis.

Cancer stem cell definitions and terminology: the devil is in the details.

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia

Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H

Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

Neoplastic stem cells: current concepts and clinical perspectives.

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Structure and assembly properties of the intermediate filament protein vimentin: the role of its head, rod and tail domains

Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.

The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils

The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

[Tumor stem cell research - basis and challenge for diagnosis and therapy].